Reported Q: Q1 2025 Rev YoY: +122.8% EPS YoY: +56.6% Move: +7.61%
Genor Biopharma Holdings
6998.HK
HKD2.97 7.61%
Exchange HKSE Sector Healthcare Industry Biotechnology
Q1 2025
Published: Mar 31, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 6998.HK

Reported

Report Date

Mar 31, 2025

Quarter Q1 2025

Revenue

16.12M

YoY: +122.8%

EPS

-0.05

YoY: +56.6%

Market Move

+7.61%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $16.12M up 122.8% year-over-year
  • EPS of $-0.05 increased by 56.6% from previous year
  • Gross margin of 100.0%
  • Net income of -27.13M
  • "N/A" - N/A
6998.HK
Company 6998.HK

Executive Summary

Genor Biopharma reported a distinctly lumpy QQ1 2025 with revenue of 16.12 million CNY, flat gross profit of 16.12 million CNY and a 100% gross margin, reflecting minimal cost of goods for the period. Revenue grew meaningfully versus QQ1 2024, rising 122.8% YoY, but sequentially the quarter collapsed from Q4 2024’s 95.88 million CNY to 16.12 million CNY, a QoQ decrease of roughly 83%. The company remains in heavy investment mode, with R&D expense of 37.28 million CNY driving overall operating expenses to 48.98 million CNY and resulting in an EBITDA loss of 30.64 million CNY and a net loss of 27.13 million CNY for QQ1 2025. The substantial R&D outlay underscores Genor’s pipeline-led strategy and the longer runway to product-commercialization milestones.

On the balance sheet, Genor shows minimal leverage and robust liquidity: a cash-per-share of 1.94 CNY and a current ratio of 4.93 indicate ample short-term liquidity to fund ongoing trials and potential collaborations, despite negative quarterly earnings. With a weighted-average share count of about 521.2 million, the diluted EPS stands at -0.0521 for QQ1 2025. Management commentary (where available) and quarterly disclosures emphasize advancement of a diversified oncology and autoimmune pipeline, including GB242 (remicade biosimilar candidate GB242), GB491 (lerociclib, a CDK4/6 inhibitor, in Phase III), GB492 (STING pathway agonist), and other candidates (GB226, GB223, GB261, etc.). Investors should monitor forthcoming trial updates, potential partnerships, and any opportunistic licensing that could translate pipeline progress into earlier-than-expected revenue inflection.

Key Performance Indicators

Revenue
Increasing
16.12M
QoQ: -83.18% | YoY: 122.84%
Gross Profit
Increasing
16.12M
1.00% margin
QoQ: -83.10% | YoY: 128.35%
Operating Income
Increasing
-32.85M
QoQ: -214.23% | YoY: 49.48%
Net Income
Increasing
-27.13M
QoQ: -172.93% | YoY: 56.83%
EPS
Increasing
-0.05
QoQ: -172.46% | YoY: 56.58%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 16.12 -0.05 -66.4% View
Q1 2025 16.12 -0.05 +122.8% View
Q4 2024 95.88 0.07 +0.0% View
Q3 2024 95.88 0.07 +0.0% View